Treating ischemic stroke as an emergency

Archives of Neurology

Volumn 55, Issue 4, 1998, Pages 457-461

  Adams Jr , Harold P ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; EMERGENCY TREATMENT; FIBRINOLYTIC THERAPY; HUMAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW;

ALGORITHMS; ARTERIAL OCCLUSIVE DISEASES; BRAIN DISEASES; EMERGENCY MEDICAL SERVICES; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PRIMARY HEALTH CARE;

EID: 2642615387     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.55.4.457     Document Type: Review

References (49)

1. Taylor TN, Davis PH, Torner JC, et al. Lifetime costs of stroke in the United States. Stroke. 1996;27:1459-1466.
2. Biller J, Love BB. Nihilism and stroke therapy. Stroke. 1991;22:1105-1107.
3. Zivin JA. Diffusion-weighted MRI for diagnosis and treatment of ischemic stroke. Ann Neurol. 1997;41:567-568.
4. Astrup J, Siesjo B, Symon L. Thresholds in cerebral ischemia: the ischemic penumbra. Stroke. 1981;12:723-725.
5. Pulsinelli W. Pathophysiology of acute ischaemic stroke. Lancet. 1992;339: 533-536.
6. Grotta J. Rodent models of stroke limitations. Arch Neurol. 1996;53:1067-1070.
7. Emergency Cardiac Care Committee and Subcommittees, American Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiac care, IV: special resuscitation situations - stroke. JAMA 1992;268:2242-2250.
8. McDowell FH, Brott TG, Goldstein M, et al. Stroke: the first six hours. J Stroke Cerebrovasc Dis. 1993;3:133-144.
9. Futrell N, Millikan CH. Stroke is an emergency. Dis Mon. 1996;42:199-264.
10. Adams HP Jr, Brott TG, Crowell RM, et al. Guidelines for the management of patients with acute ischemic stroke. Stroke. 1994;25:1901-1914.
11. Adams HP Jr, Brott TG, Furlan AJ, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of persons with acute ischemic stroke. Stroke. 1996;27:1711-1718.
12. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice advisory: thrombolytic therapy for acute ischemic stroke. Neurology. 1996;47:835-839.
13. Pan European Consensus Meeting on Stroke Management. J Intern Med. 1996; 240:173-180.
14. Broderick JP. Logistics in acute stroke management. Drugs. 1997;54(suppl 3): 109-117.
15. Marier JR, Jones PW, Emr M. Proceedings of a National Symposium on Rapid Identification and Treatment of Acute Stroke. Bethesda, Md: Office of Scientific and Health Reports, National Institute of Neurological Disorders and Stroke, National Institutes of Health; 1997. NIH publication 97-4239.
16. Alberts M, Bertels C, Dawson DV. An analysis of time of presentation after stroke. JAMA 1990;263:65-68.
17. William LS, Bruno A, Rouch D, Marriott DJ. Stroke patients' knowledge of stroke: influence on time to presentation. Stroke. 1997;28:912-915.
18. Kothari R, Sauerbeck L, Jauch E, et al. Patients' awareness of stroke signs, symptoms and risk factors. Stroke. 1997;28:1871-1875.
19. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
20. Caplan LR, Mohr JP, Kistler JP, Koroshetz W. Thrombolysis: not a panacea for ischemic stroke. N Engl J Med. 1997;337:1309-1310.
21. Grotta JC. t-PA: the best current option for most patients. N Engl J Med. 1997; 337:1310-1313.
22. Caplan LR. New therapies for stroke. Arch Neurol. 1997;54:1222-1224.
23. Caplan LR. Stroke thrombolysis: growing pains. Mayo Clin Proc. 1997;72: 1090-1092.
24. Haley EC Jr, Lewandowski C, Tilley BC, and the NINDS rt-PA Stroke Study Group. Myths regarding the NINDS rt-PA Stroke Trial: setting the record straight. Ann Emerg Med. 1997;30:676-682.
25. del Zoppo GJ, Higashida RT, Furlan AJ. The case for a phase III trial of cerebral intraarterial fibrinolysis. AJNR Am J Neuroradiol. 1994;15:1217-1222.
26. Clark WM, Warach SJ, Pettegrew LC, Gammans RE, Sabounjian LA, for the Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology. 1997;49:671-678.
27. Grotta J, Hantson L, Wessel T, for the LUB-INT-9 Lubeluzole Study. The efficacy and safety of lubeluzole in patients with acute ischemic stroke. Stroke. 1997;28:271.
28. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet. 1997;349:1569-1581.
29. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled study of early aspirin in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349:1641-1649.
30. Publications Committee for the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid Org 10172 and outcome after ischemic stroke: a randomized controlled trial. JAMA. In press.
31. Hachinski V. Thrombolysis in stroke: between the promise and peril. JAMA. 1996; 276:995-996.
32. Landi G, Cella E, Boccardi E, Musicco M. Lacunar versus non-lacunar infarcts: pathogenetic and prognostic differences. J Neurol Neurosurg Psychiatry. 1992; 55:441-445.
33. Arboix A, Garcia-Eroles L, Massons J, Oliveres M. Predictive factors of in-hospital mortality in 986 consecutive patients with first-ever stroke. Cerebrovasc Dis. 1996;6:161-165.
34. Feinberg WM, Albers GW, Barnett HJM, et al. Guidelines for the management of transient ischemic attacks. Stroke. 1994;25:1320-1335.
35. Gordon DL, Bendixen BH, Adams HP Jr, Clarke W, Kappelle LJ, Woolson RF, and the TOAST Investigators. Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke: implications for clinical trials. Neurology. 1993; 43:1021-1027.
36. Toni D, Fiorelli M, DeMichele M, et al. Clinical and prognostic correlates of stroke subtype misdiagnoses within 12 hours from onset. Stroke. 1995;26:1837-1840.
37. Brott T, Adams HP Jr, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864-870.
38. Goldstein LB, Bertels C, Davis JN. Interrater reliability of the NIH Stroke Scale. Arch Neurol. 1989;46:660-662.
39. Wityk RJ, Pessin MS, Kaplan RF, Caplan LR. Serial assessment of acute stroke using the NIH Stroke Scale. Stroke. 1994;25:362-365.
40. Goldstein LB, Samsa GP. Reliability of the National Institutes of Health Stroke Scale: extension to non-neurologists in the context of a clinical trial. Stroke. 1997; 28:307-310.
41. Pullicino P, Snyder W, Granger C. The NIH Stroke Scale and the FIM in stroke rehabilitation. Stroke. 1992;23:99.
42. Muir KW, Weir CJ, Murray GD, Povey C, Lees KR. Comparison of neurological scales and scoring systems for acute stroke prognosis. Stroke. 1996;27:1817-1820.
43. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28:2109-2118.
44. The NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA Stroke Trial. Stroke. 1997;28:2119-2125.
45. Warach SJ, Dashe JF, Edelman RR. Clinical outcome in ischemic stroke predicted by early diffusion-weighted and perfusion magnetic resonance imaging: a preliminary analysis. J Cereb Blood Flow Metab. 1996;16:53-59.
46. Koroshetz WJ, Gonzalez G. Diffusion-weighted MRI: an ECG for "brain attack?" Ann Neurol. 1997;41:565-566.
47. Lutsep HL, Albers GW, DeCrespigny A, Kamar GN, Marks MP, Moseley ME. Clinical utility of diffusion-weighted magnetic resonance imaging in the assessment of ischemic stroke. Ann Neurol. 1997;41:574-580.
48. Lovblad KO, Baird AE, Schalug G, et al. Ischemic lesion volumes in acute stroke by diffusion-weighted magnetic resonance imaging correlate with clinical outcome. Ann Neurol. 1997;42:164-170.
49. Chimowitz MI, Logigian EL, Caplan LR. The accuracy of bedside neurological diagnoses. Ann Neurol. 1990;28:78-85.